Ascendis Pharma A/S (NASDAQ:ASND) has coverage initiated with a Outperform ➝ Outperform rating

Analyst Ratings For Ascendis Pharma A/S (NASDAQ:ASND)

Story continues below

Today, Evercore ISI initiated coverage on Ascendis Pharma A/S (NASDAQ:ASND) with a Outperform .

There are 9 Buy Ratings, no Strong Buy Ratings, no Sell Ratings, no Hold Ratings on the stock.

The current consensus rating on Ascendis Pharma A/S (NASDAQ:ASND) is Buy with a consensus target price of $121.6250 per share, a potential 4.18% upside.

Some recent analyst ratings include

  • 3/25/2019-Ascendis Pharma A/S (NASDAQ:ASND) has coverage initiated with a Outperform ➝ Outperform rating
  • 3/18/2019-Ascendis Pharma A/S (NASDAQ:ASND) had its Buy rating reiterated by Cantor Fitzgerald with a $185.00 price target
  • 1/24/2019-Ascendis Pharma A/S (NASDAQ:ASND) gets upgraded to Outperform by Leerink Swann with a price target of $90.00

    About Ascendis Pharma A/S (NASDAQ:ASND)
    Ascendis Pharma A/S, a clinical stage biopharmaceutical company, develops various prodrug therapies for unmet medical needs. The company develops TransCon human growth hormone, which is in Phase III clinical study in children to treat growth hormone deficiency; TransCon parathyroid hormone that is in Phase I clinical study for treating hypoparathyroidism; and TransCon C-type natriuretic peptide for the treatment of achondroplasia. It also has strategic collaborations with Sanofi to develop TransCon Peptides for the treatment of diabetes; and Genentech and Roche to develop TransCon anti-vascular endothelial growth factor (VEGF), a compound to support injection of anti-VEGF in ophthalmology. Ascendis Pharma A/S was founded in 2006 and is headquartered in Hellerup, Denmark.

    Recent Trading Activity for Ascendis Pharma A/S (NASDAQ:ASND)
    Shares of Ascendis Pharma A/S closed the previous trading session at 116,79 −2,28 1,91 % with 124.72 shares trading hands.

    An ad to help with our costs